VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...
Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C.
Viking Therapeutics (NASDAQ: VKTX) has outperformed the market over the past 5 years by 32.8% on an annualized basis ...
In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support ...
We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Nextracker Inc (Symbol: NXT), where a total of 9,521 contracts have traded so far, ...
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
What To Know: Viking shares have experienced volatility in recent weeks, but appear to be rebounding amid broader investor interest in GLP-1 and obesity drug developers. Viking disclosed toward the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback